ATE78174T1 - Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome. - Google Patents

Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome.

Info

Publication number
ATE78174T1
ATE78174T1 AT88106401T AT88106401T ATE78174T1 AT E78174 T1 ATE78174 T1 AT E78174T1 AT 88106401 T AT88106401 T AT 88106401T AT 88106401 T AT88106401 T AT 88106401T AT E78174 T1 ATE78174 T1 AT E78174T1
Authority
AT
Austria
Prior art keywords
interferon
dacarbazin
treatment
application
malignant melanoma
Prior art date
Application number
AT88106401T
Other languages
English (en)
Inventor
Sai P Sunkara
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of ATE78174T1 publication Critical patent/ATE78174T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88106401T 1987-04-23 1988-04-21 Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome. ATE78174T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189187A 1987-04-23 1987-04-23
EP88106401A EP0288055B1 (de) 1987-04-23 1988-04-21 Anwendung von ODC-Inhibitoren, Dacarbazin und Interferon in der Behandlung bösartiger Melanome

Publications (1)

Publication Number Publication Date
ATE78174T1 true ATE78174T1 (de) 1992-08-15

Family

ID=21918900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88106401T ATE78174T1 (de) 1987-04-23 1988-04-21 Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome.

Country Status (11)

Country Link
EP (1) EP0288055B1 (de)
JP (1) JPS63280019A (de)
KR (1) KR880012239A (de)
AT (1) ATE78174T1 (de)
AU (1) AU609120B2 (de)
DE (1) DE3872749T2 (de)
DK (1) DK167905B1 (de)
ES (1) ES2051788T3 (de)
GR (1) GR3005553T3 (de)
IE (1) IE61498B1 (de)
ZA (1) ZA882719B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
IL97759A0 (en) * 1990-04-11 1992-06-21 Ciba Geigy Ag Hydroxylamine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Also Published As

Publication number Publication date
IE881221L (en) 1988-10-23
AU1502388A (en) 1988-10-27
DK222988A (da) 1988-10-24
DE3872749D1 (de) 1992-08-20
EP0288055B1 (de) 1992-07-15
GR3005553T3 (de) 1993-06-07
ES2051788T3 (es) 1994-07-01
DK167905B1 (da) 1994-01-03
ZA882719B (en) 1988-10-17
EP0288055A1 (de) 1988-10-26
IE61498B1 (en) 1994-11-02
DK222988D0 (da) 1988-04-22
JPS63280019A (ja) 1988-11-17
AU609120B2 (en) 1991-04-26
DE3872749T2 (de) 1992-12-03
KR880012239A (ko) 1988-11-26

Similar Documents

Publication Publication Date Title
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
DE297436T1 (de) Behandlung von hyperhidrose, ichtyosis und faltenbildung.
DE69715861T2 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DK0536182T3 (da) Fremgangsmåde til behandling af alopecia
DE69000248T2 (de) Verwendung von interzellularen adhaesions-molekuelen und deren bindungsliganden bei der behandlung von asthma.
DE3888994T2 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DK161320C (da) Analogifremgangsmaade til fremstilling af 2,3-diaryl-5-halogen-thiophener
FI864597A0 (fi) Kardiotoniska tiazoloner.
ATE78174T1 (de) Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome.
DE336374T1 (de) Behandlung von zusammensetzungen von polyimid-vorlaeufern.
DE3674619D1 (de) Zusammensetzung fuer baeder auf basis von psoralen in der behandlung von psoriasis.
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
ATE79615T1 (de) Cardiotonische phenyloxazolone.
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ES8403898A1 (es) Procedimiento para preparar derivados de ergolina.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee